an amino acid sequence that occurs naturally in humans, the carboxyl terminal peptide. When attached to a therapeutic protein, CTP extends the time that the protein is active in the body. The potential utility of the technology has been demonstrated by Schering-Plough, which in 2009 announced successful data from its Phase III ENGAGE trial demonstrating that women receiving a single injection of the fertility drug FSH-CTP achieved the same pregnancy rates as women receiving seven consecutive daily injections of commercial FSH. This 1,509 patient trial formed the basis for a Marketing Authorization Application by Schering-Plough that is currently under review by the European Medicines Agency. PROLOR is using the same CTP technology to extend the duration of action of human growth hormone and other therapeutic proteins. It has an exclusive license to the CTP technology from Washington University in St. Louis for use with all therapeutic proteins except for the four fertility hormones licensed to Schering-Plough.

ABOUT PROLOR BIOTECH

PROLOR Biotech, Inc. is a biopharmaceutical company applying unique technologies, including its patented CTP technology, primarily to develop longer-acting, proprietary versions of already-approved therapeutic proteins that currently generate billions of dollars in annual global sales. The CTP technology is applicable to virtually all proteins, and PROLOR is currently developing long-acting versions of human growth hormone, interferon beta and erythropoietin, which are in late preclinical development, as well as GLP-1. For more information on PROLOR, visit www.prolor-biotech.com.

(Date:3/3/2015)... Cambridge Semantics, the leading provider of smart data ... it has been named to KMWorld’s 2015 list of ... , To create the list each year, KMWorld assembles ... who identify organizations dedicated to the true value of ... right people at the right time. , “The ...

... SAN DIEGO, Nov. 5 Vical Incorporated (Nasdaq:,VICL) today reported ... the third quarter of 2008 were $0.8 million, compared,with revenues ... net loss,for the third quarter of 2008 was $9.8 million ... share for the third quarter of 2007., Revenues for ...

... TUSTIN, Calif., Nov. 4 ( http://www.amdl.com ),AMDL, Inc. ... Executive,Officer and Director, Gary L. Dreher, has retired at ... been a member of the Company,s leadership,team and a ... wishes to,Mr. Dreher on his retirement., About AMDL:, ...

(Date:2/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, announces ... CEO Conference on January 29 th at 10:30 ... CEO of NXT-ID will present and host a live ... wallet and its full suite of biometric technologies. Investors ...

(Date:1/22/2015)... CHICAGO , Jan. 9, 2015 Valid S.A. ("Company") ... the market in general the State of Washington,s ... contract for a new enrollment and central issuance system for ... The project planning and development will start ...

... interplay of brain chemicals which help us pay attention in ... By changing the way neurons respond to external stimuli we ... strength of a neuronal response, they can also affect the ... Thiele, Professor of Visual Neuroscience explains: "When you communicate with ...

... endanger the whole organism, as they may lead to ... Munich now report how byproducts of respiration cause mispairing ... in our cells controls the form and function of ... this are encoded in the linear sequence of the ...